Catheter Precision: A Distressed Micro-Cap With a Reverse-Split, a Preferred-Staple Capital Structure, and a Negative Cash Engine

The Quarter in Context

Catheter Precision, Inc. (NYSE American: VTAK) reported its second quarter ended June 30, 2026 on August 14, 2026. Q2 2026 total revenue was $1.019 million, up from $0.212 million in Q2 2025. The year-over-year jump reflects the first contribution from a private aviation segment acquired in March 2026, which generated $0.749 million in service revenue during the quarter versus no aviation revenue in the prior-year quarter. Cardiac electrophysiology product revenue (VIVO and LockeT) grew modestly to $0.270 million from $0.212 million.

Despite the top-line inflection, the quarter deepened the cash deficit. Gross profit was only $0.098 million for a 9.6% gross margin, down from 93.4% in Q2 2025 because aviation service costs run heavy while electrophysiology volume remains tiny. Selling, general and administrative expenses climbed to $3.911 million from $2.881 million a year earlier, and the operating loss was $3.955 million versus $4.686 million. Operating cash outflow for the quarter is calculated at $2.861 million using the year-to-date change (derived by subtracting the cumulative filing for the first six months of 2026 from the latest reported cumulative amount, not as a directly reported quarterly line item). Against a starting cash and marketable-securities position of roughly $0.84 million, the company finished June with $1.839 million in cash and short-term investments. Subsequent equity and debt issuance (Series C and C-4 preferred) preserved solvency, but at the cost of structural claims on the equity described below.

Business Model and Profit Engine

Catheter Precision now operates two reportable segments: cardiac electrophysiology (legacy) and private aviation (added through the March 2026 acquisition of Fly Flyte, Inc. and Ponderosa Air, LLC). In the electrophysiology segment, the company sells the VIVO non-invasive 3D cardiac mapping system and the LockeT suture retention device to hospital electrophysiology labs and vascular access sites, primarily through distributors in Europe, the Middle East, South Africa, and Brunei. Buyers purchase a recurring-use capital system (VIVO) and a per-procedure disposable (LockeT); revenue is largely transactional and depends on capital-equipment adoption cycles and procedural volumes, not recurring service contracts.

In private aviation, the company operates Cirrus Vision jets for regional charter, sourcing customers through brokers and a recently launched direct-to-consumer app. The aviation segment recognized $0.749 million in Q2 2026 service revenue against $0.899 million in cost of service revenue, producing a negative gross margin on the segment. Filing fact: cost of service revenue exceeded aviation service revenue in Q2 2026, generating a segment gross margin that is mathematically negative. That loss-making profile sits on top of a fixed-cost base that includes lease liabilities, regulatory exposure, and aircraft operating restrictions disclosed in the 10-Q risk factors.

Conversion of revenue into profit and cash is currently failing. Cost of revenue consumed 90.4% of total revenue in Q2 2026, leaving only $0.098 million of gross profit to absorb $3.911 million of selling, general and administrative expense and $0.142 million of research and development. Operating cash flow for the quarter is a calculated loss of $2.861 million (derived by subtracting six-month cumulative filings) and the trailing twelve-month operating cash outflow stands at $9.352 million. Capital intensity is low in dollar terms ($0.015 million of capex in Q2 2026), so the dominant reinvestment is corporate overhead rather than productive assets. Working capital is small: $0.120 million in accounts receivable and $0.088 million in inventory against $1.447 million in accounts payable and $1.982 million in accrued expenses. Segment contribution data is not broken out in the filing, so any cross-subsidy between aviation and electrophysiology cannot be quantified from available evidence, and that data gap is noted. Pricing power appears limited at this revenue scale: electrophysiology product revenue of $0.270 million travels through third-party distributors, and aviation pricing is broker-mediated. Observable conditions that would weaken the profit engine further include service-cost inflation in aviation, additional declines in elective EP procedure volumes, and continued reliance on dilutive preferred financings instead of operating cash to fund losses.

Earnings Quality and Cash Conversion

Where the issuer reports cash flow and capital expenditure cumulatively, the standalone-quarter cash-flow figures are derived by subtracting the preceding cumulative filing. They are calculations from SEC facts rather than separately reported quarterly line items. Reported Q2 2026 net loss was $3.295 million, modestly improved from $5.109 million a year earlier, but earnings quality is distorted by non-cash and non-recurring items. The quarter benefited from a $0.318 million change in fair value of deferred consideration and a $0.378 million unrealized gain on marketable securities, while carrying a $0.105 million loss on debt extinguishment. The income tax benefit of $0.312 million is itself a non-cash adjustment driven by deferred tax movements; it lifts reported income without any cash inflow.

Stock-based compensation in Q2 2026 was $0.266 million, up from $0.098 million in Q2 2025, an expense that does not consume cash but does consume real economic value for existing shareholders. Because diluted weighted-average share counts are not available in the available SEC data, exact dilution-adjusted EPS analysis is not possible, and that data gap is acknowledged. The trailing twelve-month operating cash outflow of $9.352 million remains the cleanest signal of the company's economic reality. Capital expenditure of $0.015 million in the quarter produces an accounting free-cash-flow proxy of negative $2.876 million; the filings do not separate maintenance from growth capex, so that proxy should not be labelled "owner earnings" or "maintenance-capex free cash flow".

Accounting free cash flow for Q2 2026 is approximately negative $2.876 million. In a separate, more conservative owner-earnings sensitivity (not an alternate definition of reported free cash flow), treating trailing twelve-month stock-based compensation of $0.479 million as an economic dilution cost produces a trailing twelve-month figure of approximately negative $9.852 million. This is an analytical approximation by the author, not a company-reported measure, and it treats compensation paid in shares as an economic cost even though the cash-flow reconciliation adds it back.

Business Quality, Moat, and Industry Position

On the available evidence, the company is best described as a theme rider, not a demonstrated core supply-chain bottleneck. This classification describes strategic position only; it is not independent proof of a moat or valuation upside. Catheter Precision operates as a micro-cap medical device and charter aviation business without visible moats. In electrophysiology, VIVO and LockeT hold FDA clearances and CE marks and benefit from patent protection (LockeT received a US patent in April 2025), but the segment competes against far larger electrophysiology platforms with deep clinical relationships and dedicated sales forces. The 10-K risk factors explicitly state that competitors have substantially greater resources and that acceptance by hospitals and physicians is uncertain. Filing fact: Q2 2026 electrophysiology product revenue was only $0.270 million, against $0.142 million of research and development in the same quarter, a ratio that does not support a claim of normalized economics.

The private aviation segment is brand-new and structurally unproven. Charter demand is broker-mediated, the app is "recently launched," and the company is still expanding routes to the Bahamas, Canada, and Mexico. The segment is operating at negative gross margin and carries regulatory and airworthiness risk exposure disclosed in detail in the 10-Q risk factors. There is no externally verifiable customer concentration data in the available evidence, and the data gap is noted.

Management and Capital Allocation

Capital allocation in 2026 has been dominated by survival financing. The company issued Series C-1, C-2, C-3, C-4, and D Convertible Preferred Stock during the quarter, much of it as acquisition consideration for the FLYTE/Ponderosa deal and as bridge capital. Filing fact: the Series C preferred has a variable conversion price that the company itself reduced from a $0.35 floor to $0.23 on August 10, 2026, and the conversion price is subject to further downward adjustment based on trading price. The 10-Q risk factor language quantifies the impact: existing and contingent preferred conversion rights represent roughly 27,874% of common shares outstanding as of August 10, 2026, and a worst-case full conversion would leave existing common stockholders with less than 3.6% of the post-conversion equity.

Management (CEO David A. Jenkins and CFO Philip Anderson) has also layered in related-party notes and royalty arrangements. Prior royalty rights held by Mr. Jenkins and affiliates were converted into 9,490 shares of Series J Convertible Preferred Stock on December 31, 2025. Related-party notes payable and interest accrued totaled several million dollars as of year-end 2025, with maturity dates now extending into 2028-2029. No dividends or share repurchases are disclosed, and the auditor has not classified the company as a going concern, but management's own risk factors explicitly state that additional capital must be raised to continue operations. Author inference (not filing fact): the pace and structure of preferred issuance during 2026 indicate management is prioritizing continued operation over per-share value preservation for common holders.

Valuation and What the Market Already Expects

The dated market snapshot (September 21, 2026) shows a share price of $0.1455 and a market capitalization of $2,760,433 on 14,391,944 shares of common stock outstanding as of August 10, 2026. On a simple share-count basis, the equity is priced at roughly 1.4x trailing twelve-month revenue of $1.915 million. The dated market capitalization is dramatically smaller than stockholders' equity of $17.561 million at June 30, 2026. Tangible book value is negative $11.585 million because $12.962 million of goodwill and $18.601 million of net intangibles sit against the equity base.

What does the current price imply? Even before considering the FLYTE/Ponderosa acquisition and the contingent preferred conversion rights, the dated equity value assigns essentially no credit to the private aviation segment, which just generated a quarterly loss, and assigns a deeply discounted value to electrophysiology. Author inference (not filing fact): the price reflects both operating-cash deterioration and the expected dilution from the Series C and Series D preferred structures, since the company itself states that existing preferred conversion rights represent approximately 6,673% of current common shares outstanding and contingent C-4 rights would push that to approximately 27,874%. No traditional earnings multiple is meaningful here; trailing twelve-month net loss is $13.005 million, and a price-to-earnings calculation would yield a meaningless negative number, so a P/E figure is omitted as the policy specifies when earnings are non-meaningful.

Ten-Year Cash Flow to Fair Market Value

Direct compounding of free cash flow over ten years is invalid in this case because the trailing twelve-month free-cash-flow proxy is negative $9.373 million and the most recent quarter produced an accounting free-cash-flow proxy of negative $2.876 million, against negligible capital expenditure. With a negative base, standard ten-year compounding is undefined. Three normalization paths are therefore presented as explicit author assumptions, not as stated forecasts.

In the bear path, the author assumes the trailing twelve-month revenue base of $1.915 million holds roughly flat (zero growth, an explicit assumption), and FCF margin remains negative through year ten; the dated market capitalization already prices this in. In the base path, the author assumes revenue compounds at 25% annually for ten years from the trailing twelve-month base, reaching approximately $18.6 million in year ten (an explicit assumption), and that FCF margin reaches 10% by year ten, producing roughly $1.86 million of FCF (an explicit assumption). At a 10% required FCF yield on year-ten cash flow (an explicit author assumption, not an audited fair value), the implied year-ten equity value is approximately $18.6 million, only modestly above the dated market capitalization. In the bull path, revenue compounds at 40% annually from the trailing twelve-month base to roughly $42.3 million in year ten, FCF margin reaches 15% by year ten for approximately $6.3 million of FCF (an explicit author assumption), and a 10% yield on that year-ten FCF yields an implied year-ten equity value near $63 million. The bull path requires both sustained execution and substantial new financing, neither of which is visible in the available filings. Each of these paths is reproducible from the stated assumptions and the available revenue base; none is an audited fair value. The qualitative reverse-DCF observation is that the dated $2.76 million market capitalization is consistent only with the bear or early-base assumptions; it does not embed meaningful credit for the bull scenario.

Five Value-Investing Lenses

Benjamin Graham Lens

Graham's framework asks whether the security trades below a defensible floor anchored to assets, normalized earnings, and balance-sheet resilience. Tangible book value at June 30, 2026 is negative $11.585 million because goodwill and intangibles from the FLYTE acquisition exceed stockholders' equity. The company is loss-making at the operating and net levels and has been for multiple periods, with a $19.155 million trailing twelve-month operating loss and a $13.005 million trailing twelve-month net loss. There is no current-asset earnings protection because working capital is small relative to debt-like obligations, and the going-concern risk factor is explicit. The dated price does not provide a margin of safety under Graham's discipline; it prices an unproven operating turnaround against a heavily dilutive capital structure, which is speculation rather than investment by Graham's definition.

Benjamin Franklin Lens

Franklin's modern application of capital discipline and opportunity cost asks whether each incremental dollar of capital is being deployed productively. The 2026 financing actions deployed preferred-stock proceeds primarily into an aviation acquisition that produced negative gross margin in its first reporting quarter and into continued operating losses in electrophysiology. Cumulative cash used in operating activities over the first half of 2026 was $5.657 million, while cumulative proceeds from equity and equity-classified contracts were $6.919 million plus $0.601 million in deferred stock issuance, a pattern in which each new dollar of outside capital is consumed faster than it is raised. Franklin's framework suggests the opportunity cost of continued dilution is the permanent loss of common-stockholder position rather than productive compounding, because every round of preferred reduces the residual equity claim of the existing common base by multiples.

Warren Buffett Lens

Buffett's owner-earnings lens asks whether the business throws off cash available to owners after maintenance reinvestment. The accounting free-cash-flow proxy (operating cash flow minus total capex) was negative $2.876 million in Q2 2026 and negative $9.373 million over the trailing twelve months, against negligible capex of $0.015 million in the quarter and $0.021 million over the trailing twelve months. The filings do not separate maintenance from growth capex, so the proxy should not be called owner earnings, and the gap is acknowledged. Capital allocation under Buffett's framework would view the repeated issuance of variable-conversion preferred stock as anti-owner behavior, because each issuance transfers future economics to preferred holders at prices that may reset downward. Without positive owner cash flow, no owner-economics bridge from cash to equity value is meaningful, and the absence of a moat reinforced by scale, switching costs, or network effects argues against a quality-business discount.

Charlie Munger Lens

Munger would invert the question: what is the most likely reason this investment fails permanently, and is management honest about it? Management does disclose dilution math explicitly, and the 10-Q is candid that further reduction of conversion floors is at the company's discretion. The most plausible permanent-loss path is that the company raises more preferred to bridge aviation losses and electrophysiology commercialization, each round of preferred converts at lower prices, and existing common stockholders are diluted below a de minimis share of the eventual equity. Related-party royalty conversions and related-party note extensions indicate that management's incentives are aligned with continued corporate survival rather than with maximizing per-share common value. Munger would also note the bias risk: a micro-cap turnaround narrative is seductive, but the available filings show no operating evidence that the business can self-fund, and the aviation segment is structurally a different industry from the core EP business, compounding the competence question.

Li Lu Lens

Li Lu's framework prioritizes circle of competence, durable advantage, culture, and permanent-loss control. A medical-device micro-cap with an unproven aviation subsidiary and a variable-conversion preferred-heavy capital structure sits at the edge of the circle of competence for most public investors, including those applying Li Lu's discipline. Durable advantage evidence is thin: FDA clearances exist, but unit volumes are too small to demonstrate pricing power or scale economics. Culture evidence is mixed; related-party transactions are disclosed in detail, which is positive for transparency, but the repeated conversion of royalty rights into preferred held by the CEO raises governance questions that the filings alone cannot resolve. Permanent-loss control is weak: a common stockholder can be diluted to a fraction of one percent of post-conversion equity under stated filing scenarios, which is not a controllable loss but a near-certain one if new financings continue.

Risks, Disconfirming Evidence, and What Would Prove This Thesis Wrong

Prominent growth narratives can amplify attention bias and the price investors are willing to pay before cash flows arrive. That does not negate the operating evidence, but it raises the burden of proof for valuation and makes execution shortfalls more costly. Three observable thesis breakers could shift the conclusion. First, if the private aviation segment generated sustained positive service gross margin for two consecutive quarters and demonstrated double-digit revenue growth, the bull-case path becomes plausible rather than hypothetical. Second, if the company executed a non-dilutive financing (such as a long-dated debt facility at single-digit rates) large enough to fund operations through electrophysiology break-even without issuing additional variable-conversion preferred, the dilution overhang would shrink. Third, if LockeT or VIVO produced a quarter of product revenue exceeding $1 million with stable or improving gross margin, signaling that electrophysiology can scale, the operating engine would begin to support a valuation beyond the bear case.

The most likely wrong assumption is that the aviation acquisition will provide cash flow sufficient to subsidize electrophysiology commercialization in the near term; the first quarter's aviation gross margin was negative, so the data does not support that assumption today. Disconfirming evidence already in the filings includes the negative free-cash-flow proxy, the negative tangible book value, and the explicit dilution language in the 10-Q. The principal data gaps are: segment-level contribution margins, customer concentration in aviation, and any backlog or recurring-revenue disclosure for either segment. The educational-use disclaimer at the end of this article applies to all forward-looking statements and analyst judgments in this review.

Investment Conclusion

The dated $0.1455 share price and $2.76 million market capitalization are not evidence of value; they reflect a micro-cap with negative free cash flow, negative tangible book value, and a capital structure that, on the company's own disclosure, can dilute existing common stockholders by orders of magnitude. The Q2 2026 revenue inflection is real but does not yet produce gross profit, operating profit, or cash, and the aviation segment opened at a negative gross margin. Until the company demonstrates self-funded owner earnings, or executes a financing that materially reduces the dilution overhang, this name remains Avoid pending better evidence.

This article is provided for educational and informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any security. All forward-looking statements and analytical judgments reflect the author's interpretation of available public filings and market data as of the date noted and are subject to change without notice.